BR112016000282A2 - uso de antagonista de vegf em tratamento de retinopatia da prematuridade - Google Patents

uso de antagonista de vegf em tratamento de retinopatia da prematuridade

Info

Publication number
BR112016000282A2
BR112016000282A2 BR112016000282A BR112016000282A BR112016000282A2 BR 112016000282 A2 BR112016000282 A2 BR 112016000282A2 BR 112016000282 A BR112016000282 A BR 112016000282A BR 112016000282 A BR112016000282 A BR 112016000282A BR 112016000282 A2 BR112016000282 A2 BR 112016000282A2
Authority
BR
Brazil
Prior art keywords
vegf antagonist
prematurity
retinopathy
treatment
baby
Prior art date
Application number
BR112016000282A
Other languages
English (en)
Portuguese (pt)
Inventor
Burian Gabriela
Aksenov Sergey
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016000282A2 publication Critical patent/BR112016000282A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
BR112016000282A 2013-07-11 2014-07-10 uso de antagonista de vegf em tratamento de retinopatia da prematuridade BR112016000282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (1)

Publication Number Publication Date
BR112016000282A2 true BR112016000282A2 (pt) 2017-12-12

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016000282A BR112016000282A2 (pt) 2013-07-11 2014-07-10 uso de antagonista de vegf em tratamento de retinopatia da prematuridade

Country Status (14)

Country Link
US (1) US20160159893A1 (enExample)
EP (1) EP3019527A2 (enExample)
JP (1) JP2016523956A (enExample)
KR (1) KR20160030504A (enExample)
CN (1) CN105377890A (enExample)
AR (1) AR096893A1 (enExample)
AU (3) AU2014288847A1 (enExample)
BR (1) BR112016000282A2 (enExample)
CA (1) CA2917813A1 (enExample)
HK (1) HK1221231A1 (enExample)
MX (1) MX2016000385A (enExample)
RU (1) RU2676303C2 (enExample)
TW (1) TW201536317A (enExample)
WO (1) WO2015004626A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
CN108697772B (zh) 2015-12-30 2022-06-24 马歇尔大学科研协会 用于治疗视网膜病的组合物和方法
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003273299B2 (en) * 2002-09-05 2010-04-01 Medimmune, Llc Methods of preventing or treating cell malignancies by administering CD2 antagonists
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
PL1660057T3 (pl) * 2003-08-27 2012-10-31 Ophthotech Corp Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
AU2006236439B2 (en) * 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
KR20210056449A (ko) * 2007-11-07 2021-05-18 안트로제네시스 코포레이션 조산 합병증의 치료에 있어서의 제대혈의 용도
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
EP3165606A1 (en) * 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
US20140249191A1 (en) * 2011-10-20 2014-09-04 Avienne Pharmaceuticals Gmbh Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases
PL2887958T3 (pl) * 2012-08-21 2021-11-22 Opko Pharmaceuticals, Llc Formulacje liposomowe

Also Published As

Publication number Publication date
AU2014288847A1 (en) 2016-01-28
EP3019527A2 (en) 2016-05-18
HK1221231A1 (zh) 2017-05-26
RU2016104398A3 (enExample) 2018-05-31
WO2015004626A3 (en) 2015-05-28
MX2016000385A (es) 2016-04-29
WO2015004626A2 (en) 2015-01-15
TW201536317A (zh) 2015-10-01
RU2676303C2 (ru) 2018-12-27
AU2019206000A1 (en) 2019-08-01
AR096893A1 (es) 2016-02-03
AU2017204326A1 (en) 2017-07-13
JP2016523956A (ja) 2016-08-12
RU2016104398A (ru) 2017-08-16
KR20160030504A (ko) 2016-03-18
CN105377890A (zh) 2016-03-02
CA2917813A1 (en) 2015-01-15
US20160159893A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
BR112016000282A2 (pt) uso de antagonista de vegf em tratamento de retinopatia da prematuridade
BR112016000177A2 (pt) usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
Draelos et al. Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study
PH12016500732A1 (en) Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
BR112015009579A2 (pt) uso de glutamina, bifidobacterium breve e pelo menos um oligossacarídeo não digerível, kit de partes, composição nutricional, e método não terapêutico para melhora do desempenho cognitivo, desenvolvimento cognitivo, desempenho comportamental, desenvolvimento comportamental e/ou interação social em um bebê ou criança
BR112013024199A2 (pt) métodos para melhorar a saúde óssea em bebês usando prebióticos
BR112014012628B8 (pt) Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
MX2016006574A (es) Composiciones nutritivas adaptadas a la edad con un contenido de proteina variable.
BR112012033064A2 (pt) programação precoce de função cerebral através de alimentação com proteína de soja
BR112016002276B8 (pt) grupo de ancoragem para um fixador externo
Fareed et al. Psychoimmunomodulatory activity of Salvadora persica L.(Miswak) extract on stress model in rats
BR112015021781A2 (pt) alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes
MX374376B (es) Uso de un suero de leche dulce que contiene una fórmula infantil para promover el desarrollo neuronal posnatal del tracto gastrointestinal del infante, y el establecimiento de las funciones intestinales que lo controlan.
Suzuki et al. Questionnaire survey on burden of medication assistance to caregiver
XU et al. Expressions of progestrone and dehydroepiandrosterone sulfate in serum and the influence of drug in 36 infantile with spasms
Hoxha et al. Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants
Pineda et al. The efficacy of dunstan baby language in decreasing the parenting stress levels of housewives with 0-2 month old infants: A quasi-experimental study
Social Security Administration Revised Medical Criteria for Evaluating Respiratory System Disorders. Final rule
Block Getting Truculent with Truncal Rashes
Bujan Rivas Injection site reactions and alopecia: 5 case reports
Norman Ibuprofen/valproic acid
Baldassarre et al. Breastfeeding: Nutrition and Behavior.
Abashev et al. Cytoprotective effect of fullerene C 60 derivatives with different structures
Келдиёров The principle of presentation of tales and stories in Khusayn Khorazmi’s “Djavokhir-ul-A sror”

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]